Tower Research Capital (TRC)’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,449
| Closed | -$31.1K | – | 5610 |
|
|
2025
Q4 | $31.1K | Sell |
3,449
-3,393
| -50% | -$25.4K | ﹤0.01% | 2781 |
|
|
2025
Q3 | $21.3K | Sell |
6,842
-29,992
| -81% | -$79.5K | ﹤0.01% | 3259 |
|
|
2025
Q2 | $78.8K | Buy |
36,834
+28,407
| +337% | +$45.9K | ﹤0.01% | 2575 |
|
|
2025
Q1 | $9.69K | Buy |
8,427
+519
| +7% | +$891 | ﹤0.01% | 3742 |
|
|
2024
Q4 | $17.3K | Sell |
7,908
-794
| -9% | -$1.8K | ﹤0.01% | 3314 |
|
|
2024
Q3 | $19K | Sell |
8,702
-3,356
| -28% | -$7.72K | ﹤0.01% | 3267 |
|
|
2024
Q2 | $27.9K | Sell |
12,058
-2,647
| -18% | -$11K | ﹤0.01% | 3543 |
|
|
2024
Q1 | $80.9K | Sell |
14,705
-5,222
| -26% | -$23.9K | ﹤0.01% | 1955 |
|
|
2023
Q4 | $49.2K | Buy |
19,927
+18,620
| +1,425% | +$177K | ﹤0.01% | 3144 |
|
|
2023
Q3 | $45.4K | Buy |
1,307
+634
| +94% | +$21.9K | ﹤0.01% | 2625 |
|
|
2023
Q2 | $22.1K | Buy |
673
+229
| +52% | +$7.89K | ﹤0.01% | 3301 |
|
|
2023
Q1 | $15K | Sell |
444
-62
| -12% | -$2.41K | ﹤0.01% | 3827 |
|
|
2022
Q4 | $16K | Sell |
506
-1,490
| -75% | -$44.1K | ﹤0.01% | 3382 |
|
|
2022
Q3 | $70K | Buy |
1,996
+183
| +10% | +$4.05K | ﹤0.01% | 2867 |
|
|
2022
Q2 | $22K | Buy |
1,813
+852
| +89% | +$12.7K | ﹤0.01% | 3710 |
|
|
2022
Q1 | $13K | Buy |
961
+414
| +76% | +$5.53K | ﹤0.01% | 4006 |
|
|
2021
Q4 | $11K | Buy |
+547
| New | +$10.4K | ﹤0.01% | 4465 |
|
Other funds holding VTYX
Tower Research Capital (TRC)'s VTYX Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 3,449 shares — an estimated $31.1K sold.
Tower Research Capital (TRC) first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $80.9K in Q1 2024. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,449 Ventyx Biosciences shares in Q1 2026, an estimated $31.1K.
- Tower Research Capital (TRC) first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Ventyx Biosciences position peaked at $80.9K in Q1 2024.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.